Price movement over the last 24 hours
Global X MSCI Argentina ETF vs Becton Dickinson and Co — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Becton Dickinson and Co trades at $151.94 (market cap $41.87B). The key difference: Becton Dickinson and Co pays a 2.76% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| ARGT | BDX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $185.39 |
52-Week Low | $67.55 | $135.49 |
Market Cap | — | $41.87B |
Enterprise Value | — | $58.33B |
Dividend Yield | — | 2.76% |
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
BDX trades at $151.94, up 0.72% on the day, with a bearish technical signal despite recent earnings beats. The stock is supported by consistent revenue growth, reaching $21.84B in 2025, and a forward P/E of 26.52. Analyst consensus is mixed with a $173.40 price target, and the company maintains a solid dividend, recently paying $1.05 per share. Cash flow trends show variability, with 2025 net cash flow negative $1.00B, though 2026 projects a positive $346M.
The outlook for BDX balances strong fundamentals against near-term headwinds. Revenue growth and strategic positioning in medical technology offer upside, but investor sentiment is cautious due to bearish technicals and margin pressures. Risks include hospital spending caution and competitive dynamics. The stock presents a hold case for long-term investors, with potential catalysts from continued earnings outperformance and innovation in healthcare technology.
Trailing returns across standard periods
Latest headlines on both assets
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →